United Therapeutics Corporation
UTHR
$515.46
-$12.45-2.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.23% | -1.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.23% | -1.10% | |||
| Cost of Revenue | -25.41% | 29.01% | |||
| Gross Profit | 5.51% | -5.63% | |||
| SG&A Expenses | 12.28% | -3.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.70% | 5.29% | |||
| Operating Income | 1.53% | -8.84% | |||
| Income Before Tax | 17.09% | -28.31% | |||
| Income Tax Expenses | -8.53% | -45.55% | |||
| Earnings from Continuing Operations | 21.13% | -24.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.13% | -24.54% | |||
| EBIT | 1.53% | -8.84% | |||
| EBITDA | 1.89% | -8.36% | |||
| EPS Basic | 23.69% | -24.89% | |||
| Normalized Basic EPS | -3.42% | -5.06% | |||
| EPS Diluted | 24.91% | -24.44% | |||
| Normalized Diluted EPS | -2.53% | -4.42% | |||
| Average Basic Shares Outstanding | -2.07% | 0.46% | |||
| Average Diluted Shares Outstanding | -2.97% | -0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||